Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.
暂无分享,去创建一个
[1] J. Gisbert,et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. , 2021, Journal of Crohn's & colitis.
[2] M. Naganuma. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis , 2020, Journal of Gastroenterology.
[3] H. Ogata,et al. Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine , 2020, Journal of gastroenterology and hepatology.
[4] J. Tosca,et al. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study , 2019, United European gastroenterology journal.
[5] A. Huitema,et al. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review , 2019, Digestion.
[6] O. Spigset,et al. Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis , 2019, Alimentary pharmacology & therapeutics.
[7] E. Siebelink,et al. Extrinsic wheat fibre consumption enhances faecal bulk and stool frequency; a randomized controlled trial. , 2019, Food & function.
[8] Jason R. Baker,et al. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. , 2017, Molecular pharmaceutics.
[9] P. Siersema,et al. Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease: A Comparison of Tools , 2016, Inflammatory bowel diseases.
[10] L. Denson,et al. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis , 2016, Inflammatory bowel diseases.
[11] E. Clementi,et al. Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug , 2015, Gastroenterology research and practice.
[12] R. D'Incà,et al. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. , 2013, World journal of gastroenterology.
[13] R. D'Incà,et al. W1213 Determination of 5-ASA and Its Derivatives in the Colonic Mucosa of Ulcerative Colitis Patients: A Surrogate Marker of Oxidative Damage? , 2009 .
[14] J. Auwerx,et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ , 2005, The Journal of experimental medicine.
[15] S. Weir,et al. Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man , 2004, European Journal of Clinical Pharmacology.
[16] A. Forbes,et al. Review article: oral, modified‐release mesalazine formulations — proprietary versus generic , 2003, Alimentary pharmacology & therapeutics.
[17] H. Ogata,et al. Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine , 2001, Inflammatory bowel diseases.
[18] E. Denamur,et al. Identification and Functional Characterization of Arylamine N-Acetyltransferases in Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid , 2001, Journal of bacteriology.
[19] D. Rampton,et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs , 2001, Gut.
[20] T. Vree,et al. Liver and gut mucosa acetylation of mesalazine in healthy volunteers. , 2000, International journal of clinical pharmacology and therapeutics.
[21] R. Giacomelli,et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis , 2000, Gut.
[22] D. Fleisher,et al. Intestinal metabolism and transport of 5-aminosalicylate. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[23] S. Riley,et al. Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[24] S. Lewis,et al. Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.
[25] M. Rijk,et al. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. , 1992, Scandinavian journal of gastroenterology.
[26] J. Rask-Madsen,et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.
[27] R. Hornung,et al. Estimation of Average Concentration in the Presence of Nondetectable Values , 1990 .
[28] U. Klotz,et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. , 1989, Gastroenterology.
[29] J. Rask-Madsen,et al. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. , 1988, Gut.
[30] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[31] C. Deighton,et al. Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis. , 1987, Gut.
[32] M. Tarlow,et al. A comparison of stool fluid and stool dialysate obtained in vivo , 1974, Gut.